Methods and compositions for modulating shp2

By designing compound I to combine HSP90 and SHP2, selective degradation of SHP2 protein was achieved, solving the problems of non-specific degradation and drug resistance of target proteins in TPD technology, and demonstrating anti-cancer potential.

CN122249436APending Publication Date: 2026-06-19RANOK THERAPEUTICS (HANGZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
RANOK THERAPEUTICS (HANGZHOU) CO LTD
Filing Date
2024-07-18
Publication Date
2026-06-19

Smart Images

  • Figure SMS_6
    Figure SMS_6
  • Figure SMS_44
    Figure SMS_44
  • Figure SMS_49
    Figure SMS_49
Patent Text Reader

Abstract

This document discloses compounds having formula I: SHP-L-Hs (I) and pharmaceutically acceptable salts thereof, wherein SHP is a chemical entity that binds to the SHP2 protein, L is a linker, and Hs is a chemical entity that binds to the HSP90 protein. Pharmaceutical compositions comprising the disclosed compounds and their use in treating diseases responsive to SHP2 protein regulation are also provided.
Need to check novelty before this filing date? Find Prior Art